A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab As Induction Therapy in Patients with Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Siplizumab (Primary)
- Indications Liver transplant rejection
- Focus Adverse reactions
- Acronyms SET-SAIL
Most Recent Events
- 04 Nov 2024 Status changed from not yet recruiting to recruiting.
- 14 Jun 2024 New trial record